Prestige Consumer Healthcare (NYSE:PBH) Given New $88.00 Price Target at Canaccord Genuity Group

Prestige Consumer Healthcare (NYSE:PBH) had its price objective decreased by equities researchers at Canaccord Genuity Group from $100.00 to $88.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target points to a potential upside of 47.03% from the company’s current price.

A number of other research firms also recently commented on PBH. Jefferies Financial Group decreased their price objective on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a report on Monday, October 27th. Sidoti upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target on the stock in a report on Wednesday, September 24th. Oppenheimer reduced their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a report on Tuesday, October 21st. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Finally, Wall Street Zen cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $85.33.

Prestige Consumer Healthcare Stock Performance

PBH traded down $1.51 during trading on Friday, reaching $59.85. The company’s stock had a trading volume of 578,048 shares, compared to its average volume of 417,607. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The company’s fifty day moving average price is $63.14 and its 200-day moving average price is $73.36. Prestige Consumer Healthcare has a 52-week low of $59.51 and a 52-week high of $90.04. The company has a market capitalization of $2.95 billion, a price-to-earnings ratio of 14.05, a price-to-earnings-growth ratio of 1.93 and a beta of 0.41.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business had revenue of $274.11 million during the quarter, compared to analysts’ expectations of $257.14 million. During the same period last year, the firm earned $1.09 EPS. The company’s quarterly revenue was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently modified their holdings of PBH. Concurrent Investment Advisors LLC acquired a new position in Prestige Consumer Healthcare in the 1st quarter valued at $361,000. Envestnet Asset Management Inc. grew its position in shares of Prestige Consumer Healthcare by 6.4% in the first quarter. Envestnet Asset Management Inc. now owns 180,802 shares of the company’s stock valued at $15,544,000 after purchasing an additional 10,876 shares during the period. Bridges Investment Management Inc. grew its position in shares of Prestige Consumer Healthcare by 38.4% in the first quarter. Bridges Investment Management Inc. now owns 3,774 shares of the company’s stock valued at $324,000 after purchasing an additional 1,048 shares during the period. Cerity Partners LLC increased its stake in Prestige Consumer Healthcare by 3.7% in the first quarter. Cerity Partners LLC now owns 3,666 shares of the company’s stock valued at $315,000 after purchasing an additional 132 shares during the last quarter. Finally, Xponance Inc. lifted its position in Prestige Consumer Healthcare by 5.5% during the first quarter. Xponance Inc. now owns 3,766 shares of the company’s stock worth $324,000 after buying an additional 196 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.